Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;41(8):2315-2317.
doi: 10.1161/ATVBAHA.121.316513. Epub 2021 Jun 24.

Nrg1β as a Proangiogenesis Therapy: How Is Nrg1β Therapy Unique From Other Angiogenesis Therapies?

Ying H Shen  1 , Jun-Ichi Abe  2
Affiliations
Editorial

Nrg1β as a Proangiogenesis Therapy: How Is Nrg1β Therapy Unique From Other Angiogenesis Therapies?

Ying H Shen et al. Arterioscler Thromb Vasc Biol. 2021 Aug.
No abstract available

Keywords: Editorials; angiogenesis; cardiomyopathy; endothelium; hypoxia; inflammation; remote ischemic preconditioning.

PubMed Disclaimer

Figures

Figure
Figure. Pro-angiogenetic factors and NRG1β.
NRG1β protects the heart through several mechanisms. NRG1β directly associates with ERbB3/4 receptor in endothelial cells (ECs) and subsequently activates ErbB2 by inducing the heterodimerization between ErbB2 and ERbB3/4. ErbB2 activation not only inhibits ATG5-mediated Trx2 degradation and EC apoptosis, but also increases NO production by activating Src signaling-mediated eNOS tyrosine phosphorylation. Different from the pro-angiogenic cytokines (such as CXCL12-CXCR4, CXCL11-CXCR7, and CCL2-CCR2) that promote inflammation in addition to inducing VEGF/VEGFR expression and angiogenesis, the pro-angiogenic NRG1β reduces inflammation by inhibiting pro-inflammatory signaling such as STAT3 and NF-κB. The anti-inflammatory characteristics of NRG1β-ErbB2 signaling may provide a unique opportunity for developing NRG1β pro-angiogenic therapies after myocardial infarction. Created with BioRender.com. mtROS, mitochondrial ROS
See this image and copyright information in PMC

Comment on

References

    1. Wan A, Rodrigues B. Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy. Cardiovasc Res. 2016:111:172–183. - PMC - PubMed
    1. Wagner JUG, Dimmeler S. Cellular cross-talks in the diseased and aging heart. J Mol Cell Cardiol. 2020:138:136–146. - PubMed
    1. Colliva A, Braga L, Giacca M, Zacchigna S. Endothelial cell-cardiomyocyte crosstalk in heart development and disease. J Physiol. 2020:598:2923–2939. - PMC - PubMed
    1. Erkens R, Totzeck M, Brum A, Duse D, Botker HE, Rassaf T, Kelm M. Endothelium-dependent remote signaling in ischemia and reperfusion: Alterations in the cardiometabolic continuum. Free Radic Biol Med. 2021:165:265–281. - PubMed
    1. Heusch G The Coronary Circulation as a Target of Cardioprotection. Circ Res. 2016:118:1643–1658. - PubMed

LinkOut - more resources